ArticleScientific reports2025
The Resilience on Amphetamine Relapse Youth Scale: development and psychometric properties.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
There is a lack of valid instruments to measure resilience among adolescents with amphetamine relapse. This study aimed to develop a standard instrument for measuring resilience to amphetamine relapse among adolescents. The study was carried out in two stages: item development through in-depth interviews and pilot testing, followed by validation with a sample of 405 adolescent amphetamine users aged 12 to 24 years via a cross-sectional survey. The resulting 41-item the Resilience on Amphetamine Relapse Youth (RARY) Scale consisted of six components: using life skills and other strategies independently (13 items), relying on family support (9 items), demonstrating self-reliance or hardiness (7 items), seeking other forms of support (5 items), anticipating negative consequences of amphetamine use (3 items), and expecting future success (4 items). The key statistical metrics, including the 5-point Likert scale, internal consistency (Cronbach's Alpha = 0.966), and factor loadings (KMO = 0.935 and Bartlett's Test is significant p-value < 0.001) are excellent. The scale's validity-content, concurrent, congruent, convergent, and discriminant-was confirmed through Pearson correlation coefficients with other relevant instruments. The exploratory factor analysis confirmed these components. This scale is deemed valid and reliable for use in Thailand and other similar sociocultural contexts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.